← Aurinia Pharmaceuticals Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Revenue $173k $420k $463k $318k $50.1m $45.6m $134.0m $175.5m $235.1m $283.1m
Total Revenue $173k $420k $463k $318k $50.1m $45.6m $134.0m $175.5m $235.1m $283.1m
Revenue From Interest $27k $1.0m $2.2m $2.7m — — — — — —
Cost of Goods and Services Sold $20k $49k $55k $37k $5.9m $1.1m $5.7m $14.1m $28.2m $32.7m
Gross Profit (Calculated) (derived) $153k $371k $408k $281k $44.2m $44.5m $128.4m $161.4m $206.9m $250.4m
Operating Expenses — — — — $154.4m — — — $239.8m $178.1m
Operating Income (Loss) — — — — ($104.3m) ($180.7m) ($111.5m) ($91.7m) ($4.7m) $104.9m
Additional Financial Items
Amortization of Intangible Assets $1.5m $1.4m $1.5m $1.4m $1.3m $2.1m $2.1m $1.7m $900k $800k
Depreciation Right of Use Assets — — — $124k — — — — — —
Finance Income $27k $702k $2.2m — — — — — — —
Income (Loss) from Continuing Operations before Income Taxes, Domestic $25.0m $46.9m $54.1m $85.2m ($61.0m) ($180.4m) ($112.4m) ($90.2m) ($8.4m) $103.9m
Interest Income, Other — — — — $1.5m $529k — — — —
Profit Loss Before Tax — — ($64.0m) ($123.7m) — — — — — —
Profit Loss From Operating Activities ($25.0m) ($46.9m) ($54.1m) ($85.2m) — — — — — —
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $25.0m $46.9m $54.1m $85.2m ($102.8m) ($180.2m) ($106.4m) ($77.5m) $7.4m $114.2m
Net Income (Loss) Attributable to Parent ($25.0m) ($46.9m) ($64.0m) ($123.7m) ($102.7m) ($181.0m) ($108.2m) ($78.0m) $5.8m $287.2m
Earnings Per Share, Basic ($0.66) ($0.92) ($0.76) ($1.33) — ($1.40) ($0.76) ($0.54) $0.04 $2.14
Earnings Per Share, Diluted ($0.66) ($0.92) ($0.76) ($1.33) — ($1.40) ($0.76) ($0.54) $0.04 $2.07
Weighted Average Number of Shares Outstanding, Basic — — — — — — 141.9m 143.2m 143.1m 134.4m
Weighted Average Number of Shares Outstanding, Diluted — — — — — — 141.9m 143.2m 146.2m 138.7m
Research and Development Expense $14.5m $33.9m $41.4m $52.9m $50.3m $51.1m $45.0m $49.6m $20.8m $32.5m
General and Administrative Expense $7.0m $12.1m $13.7m $22.2m $96.0m $171.4m $196.4m $195.0m $172.0m $101.8m
Selling, General and Administrative Expense — — — — — $171.4m $196.4m $195.0m — —
Interest Expense (non-operating) — — — — — — — — $4.8m $4.3m
Costs and Expenses — — — — — $226.3m $245.5m $267.2m $239.8m $178.1m
Current Income Tax Expense (Benefit) — $0 $73k $144k ($94k) $760k $1.8m $551k — $3.1m
Expense From Share-Based Payment Transactions With Employees — $4.2m $6.9m $7.4m — — — — — —
Expense Relating To Short-Term Leases For Which Recognition Exemption Has Been Used — — — $67k — — — — — —
Expense Relating To Variable Lease Payments Not Included In Measurement Of Lease Liabilities — — — $79k — — — — — —
Income Tax Expense Continuing Operations $0 $0 $73k $144k ($94k) $760k $1.8m $551k $1.7m ($173.0m)
Interest Expense — — — $39k — — — $2.8m — —
Interest Expense On Lease Liabilities — — — $39k — — — — — —
Other Operating Income Expense ($2.2m) $195k $2.1m ($9.0m) — — — — — —
Professional Fees Expense $1.7m $2.1m $4.2m $4.7m — — — — — —
Restructuring Costs — — — — — — — — $23.1m $1.6m
Income Tax Expense (Benefit) $0 $0 $73k $144k ($94k) $760k $1.8m $551k $1.7m ($173.0m)
Interest Income (Expense), Nonoperating, Net — — — — — — $5.1m $17.0m — —
Other Operating Income (Expense), Net — — — — $6.8m ($574k) $1.5m ($8.4m) $4.3m ($9.5m)

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.